Description

(3E,5Z)-7-[(1R)-2β-[(E,R)-4-(3-Chlorophenoxy)-3-Hydroxy-1-Butenyl]-3α,5α-Dihydroxycyclopentan-1α-Yl]-3,5-Heptadienoic Acid Methyl Ester is a high-purity, synthetically derived prostaglandin analog with a complex stereochemistry that is critical for its biological activity. This compound serves as a key advanced intermediate in the synthesis of potent pharmaceutical agents targeting specific receptor pathways. It is primarily required by pharmaceutical R&D laboratories and fine chemical manufacturers engaged in the development of novel therapeutics, particularly in the fields of ophthalmology and cardiovascular medicine.

Application

• Pharmaceutical Intermediate: Critical building block for the synthesis of prostaglandin-based active pharmaceutical ingredients (APIs).
• Ophthalmic Drug Research: Used in the development of next-generation glaucoma and ocular hypertension treatments, such as analogs of latanoprost or travoprost.
• Cardiovascular Research: Serves as a precursor for compounds studied for their effects on vasodilation and platelet aggregation.
• Biochemical Tool Compound: Utilized in pharmacological studies to investigate prostaglandin receptor (e.g., FP receptor) signaling and function.
• Process Chemistry Development: Employed in scaling up and optimizing synthetic routes for prostaglandin manufacturing.
• Reference Standard: Acts as a high-purity analytical standard for quality control and regulatory submissions in drug development.

Basic Information

Item	Detail
Product Name	(3E,5Z)-7-[(1R)-2β-[(E,R)-4-(3-Chlorophenoxy)-3-Hydroxy-1-Butenyl]-3α,5α-Dihydroxycyclopentan-1α-Yl]-3,5-Heptadienoic Acid Methyl Ester
CAS No.	64812-64-2
Molecular Formula	C23H29ClO6
Molecular Weight	436.93 g/mol
Synonyms	Methyl (3E,5Z)-7-[(1R,2R,3R,5S)-2-[(E,3R)-4-(3-Chlorophenoxy)-3-hydroxybut-1-en-1-yl]-3,5-dihydroxycyclopentyl]hepta-3,5-dienoate; 7-[3-Hydroxy-4-(3-chlorophenoxy)-1-butenyl]-3,5-dihydroxycyclopentyl-3,5-heptadienoic Acid Methyl Ester; Prostaglandin F2α Methyl Ester Analog; 9,11,15-Trihydroxy-17-phenyl-18,19,20-trinorprosta-5,13-dien-1-oic Acid Methyl Ester Derivative; Latanoprost Intermediate; Isopropyl Ester Prostaglandin Precursor; 13,14-dihydro-15-keto Prostaglandin F2α Methyl Ester Derivative
EINECS	Contact for details

Quality Control

Our production of this advanced intermediate adheres to strict quality management systems, ensuring batch-to-batch consistency suitable for pharmaceutical development. Quality is verified through comprehensive analytical techniques including HPLC, GC, and NMR to confirm identity, purity, and stereochemical integrity. A detailed Certificate of Analysis (COA) is provided with each shipment, documenting critical parameters. We support development under cGMP guidelines as required for clinical trial material.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). This product is hygroscopic (moisture-sensitive) and should be handled under a dry inert atmosphere (e.g., nitrogen or argon) to prevent degradation. For long-term storage, consider storing at 2-8°C.

Specification

Item	Specification
Appearance	White to off-white crystalline powder
Identification (HPLC)	Conforms to reference standard
Identification (NMR)	Conforms to structure
Assay (HPLC)	≥ 98.0%
Related Substances (HPLC)	Total impurities ≤ 2.0%
Any single unknown impurity	≤ 0.5%
Residual Solvents (GC)	Complies with ICH Q3C
Water Content (KF)	≤ 0.5%

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.